Glin4: Assessment of the Glycemic Responses to Nutritional Products

NCT06797349 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-05-23

No results posted yet for this study

Summary

This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume one serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.

Conditions

  • Glycemic Response

Interventions

DIETARY_SUPPLEMENT

First Reference product

dextrose (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT

Second reference product

dextrose (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT

Third reference product

dextrose (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT

First Concept product

Plant-Based Oat Beverage with Sugar 1 (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT

Second Concept product

Plant-Based Oat Beverage with Sugar 2 (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT

Third Concept product

Plant-Based Oat Beverage with Sugar 3 (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT

Fourth Concept product

Plant-Based Oat Beverage with Sugar 4 (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT

Fifth Concept product

Plant-Based Oat Beverage No Sugar 1(containing 25 grams of carbohydrates

DIETARY_SUPPLEMENT

Sixth Concept product

Plant-Based Oat Beverage No Sugar 2 (containing 25 grams of carbohydrates

DIETARY_SUPPLEMENT

Seventh Concept product

High calorie, high protein oral powder nutritional supplement. (containing 25 grams of carbohydrates

Sponsors & Collaborators

  • INQUIS Clinical Research

    collaborator INDUSTRY
  • Nutricia Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-23
Primary Completion
2025-03-04
Completion
2025-03-04

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06797349 on ClinicalTrials.gov